Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data BioAge Labs, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Revenue
0
9
Research and development
33.9
59
74
General and administrative
14.5
19.2
27.8
Operating expenses
48.4
78.2
102
Operating income
-48.4
-78.2
-92.8
Interest expense
7.79
2.37
0.7
Other non-operating income
-15.5
7.09
12.2
Pre-tax income
-63.9
-71.1
-80.6
Income tax
0
0
0
Net income
-63.9
-71.1
-80.6
EBITDA
-48.2
-78
-92.6
EPS, basic
-38.17
-6.63
-2.24
EPS, diluted
-38.17
-6.63
-2.24
Shares, basic (weighted)
1.67
10.7
35.9
Shares, diluted (weighted)
1.67
10.7
35.9
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
21.6
354
189
Short-term investments
0
92.2
Receivables
0
0.77
Other current assets
0.35
2.75
4.93
Total current assets
25.3
357
287
Property, plant and equipment
0.32
0.59
0.96
Lease right-of-use assets
0.2
0.2
2.79
Long-term investments
0.1
0.1
0.1
Other non-current assets
0.24
0.22
Total assets
25.9
358
295
Accounts payable
1.87
2
2.67
Accrued liabilities
4.03
3.89
4.35
Deferred revenue
7.83
5.75
Short-term debt
6
6
2.65
Total current liabilities
58.2
27.8
20.1
Long-term debt
8.2
2.5
0
Lease liabilities
0
2.33
Total liabilities
66.6
35.1
22.8
Total debt
14.2
8.5
2.65
Paid-in capital
8.14
576
605
Retained earnings
-182
-253
-333
Other comprehensive income
0.16
0.25
0.28
Shareholders' equity
-173
323
272
Total equity
-173
323
272
Total liabilities and equity
25.9
358
295
Shares outstanding
1.67
35.9
37.4
Cash flow statement
FY2024
FY2024
FY2025
Net income
-63.9
-71.1
-80.6
Depreciation and amortization
0.2
0.2
0.2
Stock-based compensation
3.02
6.98
11.7
Change in receivables
0
-0.77
Change in payables
-0.39
0.01
0.79
Cash from operations
-37.4
-51.5
-81.6
Capital expenditures
-0.17
-0.37
-0.72
Purchases of investments
0
-155
Sales and maturities of investments
0
60.3
Cash from investing
-0.27
-0.37
-95.2
Debt issued
12.5
Debt repaid
-1
-6
-6
Stock issued
0
0
17.2
Cash from financing
34.9
381
11.5
Net change in cash
-2.69
329
-165
Free cash flow
-37.5
-51.9
-82.3
Interest paid
1.16
1.42
0.61
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $7.05 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-1,026.0%
Operating income / revenue.
Net margin
-912.3%
Net income / revenue.
FCF margin
-850.7%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-846.0%
Cash from operations / revenue.
Return on equity (ROE)
-25.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-23.8%
Net income / average total assets.
Return on invested capital (ROIC)
-27.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
847.8%
Research and development expense / revenue.
Stock-based pay / revenue
135.6%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
4.7%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-15.8%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-17.7%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
235.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
17.2x
Current assets / current liabilities.
Quick ratio
16.6x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
16.6x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.00x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
0.0%
Total debt / total assets.
Liabilities / assets
5.5%
Total liabilities / total assets.
Net debt
-$318.7M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.23
Revenue / diluted weighted shares.
FCF per share
-$1.96
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.95
Cash from operations / diluted weighted shares.
Book value per share
$8.19
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
31.2x
Market cap / revenue.
P/B
0.86x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.86x
Market cap / tangible book value, when positive.
EV/Sales
0.47x
Enterprise value / revenue.
FCF yield
-27.2%
Free cash flow / market cap.
Earnings yield
-29.2%
Net income / market cap (the inverse of P/E).
What was BioAge Labs, Inc.'s revenue in fiscal 2025?
BioAge Labs, Inc. reported revenue of $9.0M for fiscal 2025.
Was BioAge Labs, Inc. profitable in fiscal 2025?
No. It reported a net loss of $80.6M.
How much free cash flow did BioAge Labs, Inc. generate in fiscal 2025?
Cash from operations of $81.6M minus capital expenditures of $719.0K left free cash flow of -$82.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.